Rockefeller Capital Management
RLAY icon

Rockefeller Capital Management’s Relay Therapeutics RLAY Stock Holding History

Rockefeller Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$46.2K Buy
2,560
+296
+13% +$5.67K ﹤0.01% 3509
2026
Q2 		$42.4K Buy
2,264
+1
+0% +$15 ﹤0.01% 3442
2026
Q1 		$22.5K Buy
2,263
+1,809
+398% +$16.2K ﹤0.01% 3666
2025
Q4 		$3.84K Buy
+454
New +$3.24K ﹤0.01% 4147
2023
Q1 		– Sell
-278
Closed -$4K – 3500
2022
Q4 		$4K Buy
+278
New +$5.32K ﹤0.01% 3400
2022
Q3 		– Sell
-1
Closed – – 4301
2022
Q2 		$0 Buy
+1
New +$21 ﹤0.01% 4345
2021
Q2 		– Sell
-2,166
Closed -$74K – 3576
2021
Q1 		$74K Buy
+2,166
New +$94K ﹤0.01% 1744

Other funds holding RLAY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Spruce Street Capital
Spruce Street Capital New York $629M AUM 210.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Rockefeller Capital Management's RLAY Position: Q3 2026 in Review

Rockefeller Capital Management increased its Relay Therapeutics (RLAY) stake by 13% in Q3 2026, buying an estimated $5.67K and bringing the position to 2,560 shares worth $46.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3509.

Rockefeller Capital Management first reported a position in RLAY in Q1 2021 and has held it in 7 quarters since. The position peaked at $74K in Q1 2021. 183 funds tracked by Wall St. Rank hold RLAY as of Q3 2026.

  • Rockefeller Capital Management held 2,560 shares of Relay Therapeutics worth $46.2K as of Q3 2026.
  • Rockefeller Capital Management bought 296 Relay Therapeutics shares in Q3 2026, an estimated $5.67K.
  • Relay Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #3509 holding.
  • Rockefeller Capital Management first reported a position in Relay Therapeutics in Q1 2021 and has held it in 7 quarters since.
  • Rockefeller Capital Management's Relay Therapeutics position peaked at $74K in Q1 2021.
  • 183 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.